 |
cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) |
|---|---|
| Trade Name | |
| Orphan Indication | Glioblastoma |
| USA Market Approval | USA |
| USA Designation Date | 2018-01-08 00:00:00 |
| Sponsor | AXIUM Pharmaceuticals, Inc.;265 Eastchester Drive, Suite 133, #201;High Point, North Carolina, 27262 |
